Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.33 |
| ▸ | POLQ | O75417 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30092912 | 1.00 | GPBAR1 (0.47) | GPBAR1ABL1TLR8DHFRGRIN1 | |
| SCHEMBL31756885 | 1.00 | GPBAR1 (0.47) | GPBAR1ABL1TLR8DHFRGRIN1 | |
| Hydrochloric Acid SCHEMBL28810216 | 0.98 | GPBAR1 (0.46) | GPBAR1ABL1TLR8DHFRGRIN1 | |
| SCHEMBL14600981 | 0.85 | GPBAR1 (0.50) | GPBAR1ABL1DHFRGRIN1GRIN2B | |
| SCHEMBL1872305 | 0.81 | GPBAR1 (0.45) | GPBAR1ABL1TLR8GRIN1GRIN2B | |
| SCHEMBL1872308 | 0.79 | GPBAR1 (0.46) | GPBAR1ABL1GRIN1GRIN2BPDE3B | |
| SCHEMBL27729990 | 0.79 | DPP4 (0.34) | GPBAR1ABL1GRM5 | |
| SCHEMBL5783181 | 0.78 | GPBAR1 (0.53) | GPBAR1ABL1DHFRPOLQ | |
| SCHEMBL23361562 | 0.76 | GPBAR1 (0.46) | GPBAR1GRIN1GRIN2BHSD11B1 | |
| SCHEMBL30980994 | 0.76 | GPBAR1 (0.46) | GPBAR1GRIN1GRIN2BHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473260-B2 | Chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of NT-814 | KaNDy Therapeutics Limited (GB) | 2025-11-18 | — | — | US | claimed |
| US-20230002322-A1 | NEW CHEMICAL PROCESS FOR MAKING 6-CHLORO-4-(4-FLUORO-2-METHYLPHENYL)PYRIDIN-3-AMINE A KEY INTERMEDIATE OF NT-814 | KaNDy Therapeutics Limited (GB) | 2023-01-05 | — | — | US | claimed |
| CN-114728906-A | Novel chemical method for preparing key intermediate 6-chloro-4- (4-fluoro-2-methylphenyl) pyridine-3-amine of NT-814 | 康堤医疗有限公司 | 2022-07-08 | — | — | CN | claimed |
| WO-2021094247-A1 | NEW CHEMICAL PROCESS FOR MAKING 6-CHLORO-4-(4-FLUORO-2-METHYLPHENYL)PYRIDIN-3-AMINE A KEY INTERMEDIATE OF NT-814 | KaNDy Therapeutics Limited (GB) | 2021-05-20 | — | — | WO | claimed |
| US-12473260-B2 | Chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of NT-814 | KaNDy Therapeutics Limited (GB) | 2025-11-18 | — | — | US | disclosed |
| US-12473260-B2 | Chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of NT-814 | KaNDy Therapeutics Limited (GB) | 2025-11-18 | — | — | US | disclosed |
| US-20230002322-A1 | NEW CHEMICAL PROCESS FOR MAKING 6-CHLORO-4-(4-FLUORO-2-METHYLPHENYL)PYRIDIN-3-AMINE A KEY INTERMEDIATE OF NT-814 | KaNDy Therapeutics Limited (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20230002322-A1 | NEW CHEMICAL PROCESS FOR MAKING 6-CHLORO-4-(4-FLUORO-2-METHYLPHENYL)PYRIDIN-3-AMINE A KEY INTERMEDIATE OF NT-814 | KaNDy Therapeutics Limited (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20230002322-A1 | NEW CHEMICAL PROCESS FOR MAKING 6-CHLORO-4-(4-FLUORO-2-METHYLPHENYL)PYRIDIN-3-AMINE A KEY INTERMEDIATE OF NT-814 | KaNDy Therapeutics Limited (GB) | 2023-01-05 | — | — | US | disclosed |
| EP-4058433-A1 | NEW CHEMICAL PROCESS FOR MAKING 6-CHLORO-4-(4-FLUORO-2-METHYLPHENYL)PYRIDIN-3-AMINE A KEY INTERMEDIATE OF NT-814 | KaNDy Therapeutics Limited (GB) | 2022-09-21 | — | — | EP | disclosed |
| CN-114728906-A | Novel chemical method for preparing key intermediate 6-chloro-4- (4-fluoro-2-methylphenyl) pyridine-3-amine of NT-814 | 康堤医疗有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728906-A | Novel chemical method for preparing key intermediate 6-chloro-4- (4-fluoro-2-methylphenyl) pyridine-3-amine of NT-814 | 康堤医疗有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2011-08-04 | — | — | US | disclosed |
| EP-2336136-A1 | Pyridine derivatives and their use in the treatment of psychotic disorders | GlaxoSmithKline LLC (US) | 2011-06-22 | — | — | EP | disclosed |
| US-7919491-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | GLAXOSMITHKLINE LLC (US) | 2010-06-17 | — | — | US | disclosed |
| US-7683056-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2008-10-30 | — | — | US | disclosed |
| EP-1928886-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | SmithKline Beecham Corporation (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007028654-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | NDUFB7, NDUFB6, GABRE | GPBAR1 1351/4885ABL1 574/4885TLR8 2879/4885 |
| US-20230002322-A1 | NEW CHEMICAL PROCESS FOR MAKING 6-CHLORO-4-(4-FLUORO-2-METHYLPHENYL)PYRIDIN-3-AMINE A KEY INTERMEDIATE OF NT-814 | NT5E, NT5M, NTRK2 | GPBAR1 3570/4885ABL1 332/4885TLR8 1596/4885 |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | SLC6A3, NDUFS5, NDUFB6 | GPBAR1 1490/4885ABL1 109/4885TLR8 2838/4885 |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | CHRNA7, NR3C2, CHRNA6 | GPBAR1 783/4885ABL1 600/4885TLR8 2057/4885 |
| US-12473260-B2 | Chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of NT-814 | NT5E, NT5M, NTRK2 | GPBAR1 3309/4885ABL1 242/4885TLR8 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.